NAPRT and ovarian carcinoma: Co-treatment with 2-HNA and FK866 prompted marked cell death of OVCAR-5 (ovarian cancer) and of Capan-1 (pancreatic cancer) cells, which both express NAPRT in abundant amounts (thereby recreating the effects of NAPRT silencing) [70].